Research ArticleSub-clinical hepatic encephalopathy in cirrhotic patients is not aggravated by sedation with propofol compared to midazolam: A randomized controlled study
Introduction
Hepatic encephalopathy (HE) is a complex neurological disorder associated with advanced liver disease of either acute or chronic nature [1]. A milder form, referred to as sub-clinical hepatic encephalopathy (minimal hepatic encephalopathy), is defined as a condition in which patients demonstrate quantifiable neuropsychological defects, yet appear to have a normal mental and neurological status on clinical examination [2]. These patients can work, operate machinery, and drive a car, yet may be at increased risk of injury [3], [4].
Endoscopy is routinely performed in patients with chronic liver disease to screen for complications related to portal hypertension such as esophageal and gastric varices and portal gastropathy [5], [6]. Sedation is frequently administered to facilitate patient tolerance [7]. Patients with hepatic dysfunction, who undergo endoscopy, are at increased risk for complications related to sedation. There are few studies quantifying the risk in this population [8]. Since most drugs are metabolized in the liver, the choice of endoscopic sedatives may place cirrhotic patients at risk for either enhanced effects of the medication due to higher plasma level or prolonged effects due to delayed clearance [9]. The standard medications, meperidine and benzodiazepines, are predominantly metabolized in the liver and cirrhosis impairs first pass clearance as well as metabolism [10]. The lower plasma levels of albumin may also decrease drug binding, leading to an increase of absorption in the tissues, prolonging clearance and thus exacerbating sub-clinical hepatic encephalopathy [11]. Midazolam is a benzodiazepine depressant of the central nervous system that is commonly used in synergy with the opioid analgesic meperidine for conscious sedation in the general population undergoing upper GI endoscopy [12], [13]. This combination is widely used because of its short-acting sedative (half-life less than 6 h for midazolam), anxiolytic, and amnesic properties [14], [15]. A major component of the half-life is the production of active metabolites that may have different half-lives. However, for midazolam, the initial metabolite, alpha-hydroxyl-midazolam, has a short half-life as well [16]. Thus, liver patients are at potentially greater risk for complications, including cardiopulmonary compromise, and possible precipitation or exacerbation of encephalopathy, including sub-clinical encephalopathy [8], [17]. Propofol is a short-acting anesthetic agent that can be successfully used as a sedative drug during GI endoscopy. It is rapidly metabolized in the liver by conjugation with glucoronic acid (phase 2 reaction) [18]. Structurally, it is a substituted phenol agent (2,6-diisopropyl phenol), which is believed to exert its effect on the central nervous system through promotion of γ-amino butyric (GABA) activity in the brain [18]. It has a favorable pharmacokinetic profile in comparison to the benzodiazepines and opioids with regard to rapid induction of sedation, faster recovery, and equivalent levels of amnesia [19], [20]. The depth of sedation produced is typically greater than with traditional sedatives used in the outpatient setting. Although propofol undergoes hepatic metabolism, no adjustments in dosage are required in patients with chronic liver disease [19], [20]. It has been used effectively and safely in a small study of cirrhotic patients who exhibited significantly shorter induction and recovery periods [21]. It was safe even in elderly individuals and in those with multiple co-morbid conditions [22]; however, the effect on hepatic encephalopathy was not investigated. More recently, a trial with a close design has been published by Riphaus et al. [23]. However, his study differs from our study by several points including the etiology of liver disease (alcohol vs. viral), selection of the control groups (healthy individuals without sedation and without endoscopy vs. healthy individuals with sedation and with endoscopy), severity of pre-existing liver disease (six patients with Child-Pugh’s Class C vs. none with Child-Pugh’s Class C), amount of propofol (50–320 mg vs. 70–100 mg), and finally the timing of the number connection test evaluation (2 h vs. 1 h). We have previously demonstrated that sedation with midazolam exacerbates sub-clinical hepatic encephalopathy in patients with Child-A or Child-B cirrhosis [17]. In this study, we have investigated the effects of propofol compared to midazolam on the degree of sub-clinical hepatic encephalopathy and mean time to achieve full recovery in patients with liver disease who are undergoing upper endoscopy screening.
Section snippets
Patients and methods
The study is a randomized controlled study in which assignments to propofol or midazolam were selected randomly (single blind study, controlled, parallel, case-only, randomized trial). The study population comprised 61 patients with compensated cirrhosis (Child-Pugh class A or B, CP score 5–7) who were undergoing diagnostic upper GI endoscopy for portal hypertension in one medical center. In control subjects (N = 30) without cirrhosis, age, gender, BMI, and education levels were matched to the
Results
Table 1 provides the clinical and biochemical characteristics of the two groups of patients and controls. When analyzed as a group; 58/61 cirrhotic patients (95%) with cirrhosis had sub-clinical encephalopathy before the endoscopy (mean NCT 80.0 ± 61 s, normal <30 s). The extent of the NCT abnormalities correlated with Child-Pugh scores (r = 0.4, p <0.001) (Fig. 1). None of the patients developed overt HE after sedation. There was no difference between cirrhotic groups in term of age, gender, BMI, CP,
Discussion
The results of this study indicate that sedation with midazolam but not propofol exacerbates sub-clinical encephalopathy and leaves patients more encephalopathic at the time of discharge from hospital than on admission for the procedure. Moreover, the results indicate that subjects receiving propofol exhibited significantly shorter induction and shorter recovery periods than those receiving midazolam. The clinical relevance of our study finding is that it results in less co-morbidity, less
Conflict of interest
The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.
Financial disclosure
The authors have no financial disclosure to declare. NCT: NCT 01141036.
References (41)
- et al.
Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th world congresses of gastroenterology, Vienna, 1998
Hepatology
(2002) Endoscopic screening for varices in cirrhosis: findings, implications, and outcomes
Gastroenterology
(2002)Toward safer sedation in patients with cirrhosis: have we done enough?
Gastrointest Endosc
(2009)Safety of endoscopy in patients with end-stage liver disease
Gastrointest Endosc Clin N Am
(2001)- et al.
Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis
Gastroenterology
(1979) - et al.
Risk of sedation for upper GI endoscopy exacerbating subclinical hepatic encephalopathy in patients with cirrhosis
Gastrointest Endosc
(1999) - et al.
Pharmacokinetics of propofol infusions in patients with cirrhosis
Br J Anaesth
(1990) - et al.
Nurse-administered propofol versus midazolam and meperidine for upper endoscopy in cirrhotic patients
Am J Gastroenterol
(2003) - et al.
Neuropsychological characterization of hepatic encephalopathy
J Hepatol
(2001) - et al.
Impairment of psychomotor responses after conscious sedation in cirrhotic patients undergoing therapeutic upper GI endoscopy
Am J Gastroenterol
(2002)
The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy, ambulant, non-shunted patients with cirrhosis
J Hepatol
Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism
Gastroenterology
Physicians, elderly drivers and dementia
Lancet
Sedation and analgesia in the paediatric intensive care unit
Ann Fr Anesth Reanim
Characteristics of minimal hepatic encephalopathy
Metab Brain Dis
Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test
Hepatology
Hepatic encephalopathy and fitness to drive
Gastroenterology
Portal hypertension and variceal hemorrhage
Med Clin N Am
Dose adjustment in patients with liver disease
Drug Saf
Binding of bilirubin and bromosulphthalein to albumin: implications for understanding the pathophysiology of liver failure and its management
Liver Transpl
Cited by (62)
Anesthesia in patients with chronic liver disease: An updated review
2023, Clinics and Research in Hepatology and GastroenterologyDexmedetomidine alleviates neuroinflammation, restores sleep disorders and neurobehavioral abnormalities in rats with minimal hepatic encephalopathy
2021, International ImmunopharmacologyPortal Hypertensive Bleeding
2019, Clinical Gastrointestinal EndoscopyKorean clinical practice guidelines for diagnostic and procedural sedation
2024, Korean Journal of Anesthesiology